SanBio Co Stock

SanBio Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of SanBio Co (4592.T) as of Aug 15, 2026 is 0.70. In the previous year, Net Debt to Free Cash Flow Ratio was 0.79 — a change of -11.00% (lower).

Net Debt/FCF

0.70

YoY

-11.00%

Last updated:

Net Debt to Free Cash Flow Ratio of SanBio Co is 2026 0.70 . Net Debt to Free Cash Flow Ratio of SanBio Co was 2025 0.79 . It decreases by -11.00% lower compared to the previous year.
Access this data via the Eulerpool API

SanBio Co Stock analysis

What does SanBio Co do? SanBio Co Ltd is a leading bio-pharmaceutical company focused on the development of products for the treatment of serious neurological diseases. The company was founded in Japan in 2000 and has since become a multinational company with offices in the USA and Europe. Answer: SanBio Co Ltd is a bio-pharmaceutical company that specializes in developing products for the treatment of serious neurological diseases. It was founded in Japan in 2000 and has expanded to become a multinational company with offices in the USA and Europe. SanBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SanBio Co stock

Net Debt to Free Cash Flow Ratio of SanBio Co is 0.70 in 2026.

Net Debt to Free Cash Flow Ratio of SanBio Co changed from 0.79 to 0.70, representing a -11.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio SanBio Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's SanBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — SanBio Co

All Key Metrics — SanBio Co